What is Glenmark Pharmaceuticals?
Founded in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals is a prominent global pharmaceutical entity engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical products. With operations spanning over 25 countries across multiple continents, Glenmark has cultivated a strong emphasis on research and development, aiming to pioneer innovative medications. The company's strategic focus encompasses various therapeutic areas, supporting both business-to-business and consumer markets worldwide through its comprehensive portfolio.
How much funding has Glenmark Pharmaceuticals raised?
Glenmark Pharmaceuticals has raised a total of $598M across 4 funding rounds:
Private Equity
$48M
Other Financing Round
$150M
Debt
$200M
Debt
$200M
Private Equity (2002): $48M with participation from Actis
Other Financing Round (2015): $150M led by Temasek Holdings
Debt (2016): $200M supported by International Finance
Debt (2020): $200M featuring International Finance
Key Investors in Glenmark Pharmaceuticals
Temasek Holdings
Temasek Holdings, a global investment company founded in 1974 and headquartered in Singapore, acts as a generational investor focused on long-term impact and sustainable development.
Actis
Actis LLP is a private equity investment firm established in 2004, with a focus on sectors including financial services, consumer goods, energy, real estate, and healthcare across global markets.
International Finance
International Finance Corporation is a multilateral financial institution dedicated to mobilizing capital and expertise for sustainable development in emerging markets, providing financial solutions and advisory services to support private sector growth.
What's next for Glenmark Pharmaceuticals?
The recent major strategic investment into Glenmark Pharmaceuticals signals a pivotal phase for the company, likely aimed at accelerating its research and development pipeline, expanding its global market reach, or bolstering its manufacturing capabilities. Given its established enterprise-level funding history, this capital infusion is expected to fuel further innovation and solidify its competitive position in the dynamic pharmaceutical landscape, particularly in emerging markets and specialized therapeutic segments.
See full Glenmark Pharmaceuticals company page
